← Leaderboards
Linda Watkins
University Of Colorado At Boulder
$19,337,839
Attributed
$20,806,598
Total exposure
19
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–22$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$20,806,598 · 19
By mechanism
R01$16,827,322 · 10
RC1$1,428,108 · 2
K02$901,832 · 2
R21$719,542 · 2
K05$616,250 · 1
R03$313,544 · 2
Top collaborators
- Daniel S. Barth6 shared
- Monika R Fleshner6 shared
- Steven F Maier6 shared
Others in their field
Top investigators on “Pain”
- Emer Leahy · Psychogenics, Inc.$49,781,254
- Lynn Larson Debar · Kaiser Foundation Research Institute$37,527,482
- J Richard Landis · University Of Pennsylvania$34,799,488
- Clifford J Woolf · Boston Children'S Hospital$30,992,766
- Emeran A Mayer · University Of California Los Angeles$29,229,798
- Pamela Susan Douglas · Duke University$28,862,172
Research focus
PainCytokineSpinal CordMicrogliaSpinalAstrocytesPainful NeuropathyPreventPharmaceutical PreparationsOpioidNeuronsNeurogliaClinically RelevantInhibitor/AntagonistMaintenanceRattusChronic PainPain ManagementResponseInvestigationBehavioralBlood - Brain Barrier AnatomyBrainMediating
Grant awards (83)
Enduring enhancement of neuropathic pain by early post-trauma morphine$530,422
R01 · FY2022 · DA · contact PI
Enduring enhancement of neuropathic pain by early post-trauma morphine$530,422
R01 · FY2021 · DA · contact PI
Targeting neuropathic pain prevention: Modulating the neuroimmunology of peripheral nerve injury$346,500
R01 · FY2021 · AT · contact PI
Enduring enhancement of neuropathic pain by early post-trauma morphine$530,422
R01 · FY2020 · DA · contact PI
Targeting neuropathic pain prevention: Modulating the neuroimmunology of peripheral nerve injury$346,500
R01 · FY2020 · AT · contact PI
Targeting toll like receptor 4 (TLR4) and TLR2 to resolve EAE-associated paralysis, pain and cognitive deficits: efficacy of a clinically-relevant blood brain barrier permeable TLR4/TLR2 antagonist$336,875
R01 · FY2020 · NS · contact PI
Enduring enhancement of neuropathic pain by early post-trauma morphine$530,422
R01 · FY2019 · DA · contact PI
Targeting neuropathic pain prevention: Modulating the neuroimmunology of peripheral nerve injury$346,500
R01 · FY2019 · AT · contact PI
Targeting toll like receptor 4 (TLR4) and TLR2 to resolve EAE-associated paralysis, pain and cognitive deficits: efficacy of a clinically-relevant blood brain barrier permeable TLR4/TLR2 antagonist$330,548
R01 · FY2019 · NS · contact PI
Enduring reversal of chronic pain by adenosine 2a agonism$192,500
R21 · FY2019 · NS · contact PI
Enduring enhancement of neuropathic pain by early post-trauma morphine$530,422
R01 · FY2018 · DA · contact PI
Targeting neuropathic pain prevention: Modulating the neuroimmunology of peripheral nerve injury$346,500
R01 · FY2018 · AT · contact PI
Targeting toll like receptor 4 (TLR4) and TLR2 to resolve EAE-associated paralysis, pain and cognitive deficits: efficacy of a clinically-relevant blood brain barrier permeable TLR4/TLR2 antagonist$336,875
R01 · FY2018 · NS · contact PI
Enduring reversal of chronic pain by adenosine 2a agonism$231,000
R21 · FY2018 · NS · contact PI
Targeting toll like receptor 4 (TLR4) and TLR2 to resolve EAE-associated paralysis, pain and cognitive deficits: efficacy of a clinically-relevant blood brain barrier permeable TLR4/TLR2 antagonist$336,875
R01 · FY2017 · NS · contact PI
Targeting neuropathic pain prevention: Modulating the neuroimmunology of peripheral nerve injury$331,381
R01 · FY2017 · AT · contact PI
Targeting toll like receptor 4 (TLR4) and TLR2 to resolve EAE-associated paralysis, pain and cognitive deficits: efficacy of a clinically-relevant blood brain barrier permeable TLR4/TLR2 antagonist$336,784
R01 · FY2016 · NS · contact PI
Preventing Transition of Acute-to-Chronic Neuropathic Pain: Models, Mechanisms &$375,872
R01 · FY2015 · DE · contact PI
Preventing Transition of Acute-to-Chronic Neuropathic Pain: Models, Mechanisms &$375,977
R01 · FY2014 · DE · contact PI
Preventing Transition of Acute-to-Chronic Neuropathic Pain: Models, Mechanisms &$100,122
R01 · FY2014 · DE · contact PI
Preventing Transition of Acute-to-Chronic Neuropathic Pain: Models, Mechanisms &$353,912
R01 · FY2013 · DE · contact PI
Preventing Transition of Acute-to-Chronic Neuropathic Pain: Models, Mechanisms &$376,182
R01 · FY2012 · DE · contact PI
Exploring the Potential of Glia for Regulating Clinically Relevant Opiod Actions$359,635
R01 · FY2012 · DA · contact PI
Immune and Gilia Regulation of Pain & Analgesic Actions$123,250
K05 · FY2012 · DA · contact PI
Exploring the Potential of Glia for Regulating Clinically Relevant Opiod Actions$15,390
R01 · FY2012 · DA · contact PI
Preventing Transition of Acute-to-Chronic Neuropathic Pain: Models, Mechanisms &$376,281
R01 · FY2011 · DE · contact PI
Exploring the Potential of Glia for Regulating Clinically Relevant Opiod Actions$359,754
R01 · FY2011 · DA · contact PI
Immune and Gilia Regulation of Pain & Analgesic Actions$123,250
K05 · FY2011 · DA · contact PI
Exploring the Potential of Glia for Regulating Clinically Relevant Opiod Actions$11,880
R01 · FY2011 · DA · contact PI
Optoid Analgesics: Modulation of Trigeminal & Spinal Glial Activation$382,856
R01 · FY2010 · DE · contact PI
Spinal adenosine modulator: enduring anti-inflammatory action in neuropathic pain$374,610
RC1 · FY2010 · NS · contact PI
Exploring the Potential of Glia for Regulating Clinically Relevant Opiod Actions$370,999
R01 · FY2010 · DA · contact PI
Models and mechanisms for the transition of acute-to-chronic orofacial pain$337,893
RC1 · FY2010 · DE · contact PI
Immune and Gilia Regulation of Pain & Analgesic Actions$123,250
K05 · FY2010 · DA · contact PI
Exploring the Potential of Glia for Regulating Clinically Relevant Opiod Actions$9,936
R01 · FY2010 · DA · contact PI
Pain facilitation via neuron-to-glia signaling$454,832
R01 · FY2009 · DA · contact PI
Optoid Analgesics: Modulation of Trigeminal & Spinal Glial Activation$412,904
R01 · FY2009 · DE · contact PI
Spinal adenosine modulator: enduring anti-inflammatory action in neuropathic pain$374,730
RC1 · FY2009 · NS · contact PI
Exploring the Potential of Glia for Regulating Clinically Relevant Opiod Actions$358,125
R01 · FY2009 · DA · contact PI
Models and mechanisms for the transition of acute-to-chronic orofacial pain$340,875
RC1 · FY2009 · DE · contact PI
Immune and Gilia Regulation of Pain & Analgesic Actions$123,250
K05 · FY2009 · DA · contact PI
Exploring the Potential of Glia for Regulating Clinically Relevant Opiod Actions$71,711
R01 · FY2009 · DA · contact PI
Exploring the Potential of Glia for Regulating Clinically Relevant Opiod Actions$42,820
R01 · FY2009 · DA · contact PI
Pain facilitation via neuron-to-glia signaling$42,820
R01 · FY2009 · DA · contact PI
Optoid Analgesics: Modulation of Trigeminal & Spinal Glial Activation$21,210
R01 · FY2009 · DE · contact PI
Pain facilitation via neuron-to-glia signaling$454,488
R01 · FY2008 · DA · contact PI
Optoid Analgesics: Modulation of Trigeminal & Spinal Glial Activation$341,869
R01 · FY2008 · DE · contact PI
Exploring the Potential of Glia for Regulating Clinically Relevant Opiod Actions$341,437
R01 · FY2008 · DA · contact PI
Immune and Gilia Regulation of Pain & Analgesic Actions$123,250
K05 · FY2008 · DA · contact PI
Optoid Analgesics: Modulation of Trigeminal & Spinal Glial Activation$71,407
R01 · FY2008 · DE · contact PI
Exploring the Potential of Glia for Regulating Clinically Relevant Opiod Actions$5,805
R01 · FY2008 · DA · contact PI
Optoid Analgesics: Modulation of Trigeminal & Spinal Glial Activation$345,766
R01 · FY2007 · DE · contact PI
Pain facilitation via neuron-to-glia signaling$315,710
R01 · FY2007 · DA · contact PI
Immune /Glial Mediation of Exaggerated Pain States$120,010
K02 · FY2007 · DA · contact PI
Pain facilitation via neuron-to-glia signaling$69,325
R01 · FY2007 · DA · contact PI
Pain facilitation via neuron-to-glia signaling$36,360
R01 · FY2007 · DA · contact PI
Optoid Analgesics: Modulation of Trigeminal & Spinal Glial Activation$353,113
R01 · FY2006 · DE · contact PI
Pain facilitation via neuron-to-glia signaling$323,051
R01 · FY2006 · DA · contact PI
Immune/Glial Mediation of Exaggerated Pain States$120,010
K02 · FY2006 · DA · contact PI
Spinal glia activation in human chronic pain$75,345
R03 · FY2006 · NS · contact PI
Pain facilitation via neuron-to-glia signaling$350,336
R01 · FY2005 · DA
Immune/Glial Mediation of Exaggerated Pain States$120,010
K02 · FY2005 · DA
Spinal glia activation in human chronic pain$89,408
R03 · FY2005 · NS
Methods Development for Studying Dorsal Spinal Cord Glia$74,500
R03 · FY2005 · DA
ALLODYNIC EFFECTS OF SCIATIC INFLAMMATORY NEURITIS$236,695
R01 · FY2004 · NS
Immune/Glial Mediation of Exaggerated Pain States$120,010
K02 · FY2004 · DA
Methods Development for Studying Dorsal Spinal Cord Glia$74,291
R03 · FY2004 · DA
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN$419,463
R01 · FY2003 · NS
ALLODYNIC EFFECTS OF SCIATIC INFLAMMATORY NEURITIS$229,804
R01 · FY2003 · NS
Pain control via spinal interleukin-10 gene therapy$148,042
R21 · FY2003 · DA
Immune /Glial Mediation of Exaggerated Pain States$120,010
K02 · FY2003 · DA
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN$375,723
R01 · FY2002 · NS
ALLODYNIC EFFECTS OF SCIATIC INFLAMMATORY NEURITIS$223,111
R01 · FY2002 · NS
Pain control via spinal interleukin-10 gene therapy$148,000
R21 · FY2002 · DA
CYTOKINE-TO-BRAIN COMMUNICATION--ROLE OF THE VAGUS$100,594
K02 · FY2002 · MH
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN$19,788
R01 · FY2002 · NS
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN$388,480
R01 · FY2001 · NS
ALLODYNIC EFFECTS OF SCIATIC INFLAMMATORY NEURITIS$302,432
R01 · FY2001 · NS
CYTOKINE-TO-BRAIN COMMUNICATION--ROLE OF THE VAGUS$100,594
K02 · FY2001 · MH
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN$414,389
R01 · FY2000 · NS
CYTOKINE TO BRAIN COMMUNICATION--ROLE OF THE VAGUS$219,520
R01 · FY2000 · MH
CYTOKINE-TO-BRAIN COMMUNICATION--ROLE OF THE VAGUS$100,594
K02 · FY2000 · MH
PAIN FACILITATION BY GP120 AND HIV ENVELOPE PROTEIN$68,584
R01 · FY2000 · NS